An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
NCT ID: NCT03844048
Last Updated: 2025-07-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE3
165 participants
INTERVENTIONAL
2019-09-06
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia
NCT03844815
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901
A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)
NCT04198415
Venetoclax in Addition to Blinatumomab in Adult Patients With Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia Relapsed/Refractory B Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL)
NCT05182385
A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy
NCT03941964
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Venetoclax
Venetoclax at the same dose administered to each subject during the previous study in which they were enrolled.
Venetoclax
oral; film-coated tablets or tablets for oral suspension
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Venetoclax
oral; film-coated tablets or tablets for oral suspension
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Male subject agrees to refrain from sperm donation.
* Female subjects must not be pregnant or breastfeeding.
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona Cancer Center - Tucson /ID# 210548
Tucson, Arizona, United States
UCLA Santa Monica Hematology Oncology /ID# 210551
Los Angeles, California, United States
Ingalls Memorial Hosp /ID# 210553
Harvey, Illinois, United States
Dana-Farber Cancer Institute /ID# 215360
Boston, Massachusetts, United States
University of Michigan Comprehensive Cancer Center Michigan Medicine /ID# 231132
Ann Arbor, Michigan, United States
Dartmouth-Hitchcock Medical Center /ID# 210555
Lebanon, New Hampshire, United States
Swedish Cancer Institute /ID# 213120
Seattle, Washington, United States
Royal Prince Alfred Hospital /ID# 239557
Camperdown, New South Wales, Australia
St George Hospital /ID# 225589
Kogarah, New South Wales, Australia
Liverpool Hospital /ID# 225591
Liverpool, New South Wales, Australia
Peter MacCallum Cancer Ctr /ID# 210559
Melbourne, Victoria, Australia
Fiona Stanley Hospital /ID# 239480
Murdoch, Western Australia, Australia
Perth Blood Institute Ltd /ID# 225592
Nedlands, Western Australia, Australia
Duplicate_Medizinische Universitaet Graz /ID# 223817
Graz, Styria, Austria
Cliniques Universitaires UCL Saint-Luc /ID# 224327
Brussels, Brussels Capital, Belgium
CHUQ- Hôpital de l'Enfant-Jesus /ID# 224616
Québec, Quebec, Canada
Rigshospitalet /ID# 224213
Copenhagen Ø, Capital Region, Denmark
Aarhus Universitetshospital - Skejby /ID# 224214
Aarhus, Central Jutland, Denmark
CHU Grenoble - Hopital Michallon /ID# 240497
La Tronche, Isere, France
HCL - Hopital Lyon Sud /ID# 213508
Pierre-Bénite, Rhone, France
General Hospital of Athens Laiko /ID# 224087
Athens, Attica, Greece
General Hospital of Thessaloniki George Papanikolaou /ID# 224088
Thessaloniki, , Greece
Queen Mary Hospital /ID# 224944
Hong Kong, , Hong Kong
Beaumont Hospital /ID# 225165
Dublin, , Ireland
Kobe City Medical Center General Hospital /ID# 241518
Kobe, Hyōgo, Japan
Duplicate_National Hospital Organization Mito Medical Center /ID# 241986
Higashi Ibaraki-gun, Ibaraki, Japan
Okayama Medical Center /ID# 241517
Okayama, Okayama-ken, Japan
National Cancer Center Hospital /ID# 241516
Chuo-ku, Tokyo, Japan
Centro de Investigacion Clínica Chapultepec SA de CV /ID# 227018
Morelia, Michoacán, Mexico
Hospital Universitario Dr. Jose Eleuterio Gonzalez /ID# 227017
Monterrey, Nuevo León, Mexico
Aotearoa Clinical Trials /ID# 225596
Papatoetoe, Auckland, New Zealand
North Shore Hospital /ID# 225597
Takapuna, Auckland, New Zealand
Wellington Regional Hospital /ID# 225593
Newtown, Wellington Region, New Zealand
Duplicate_Pratia MCM Krakow /ID# 218561
Krakow, Lesser Poland Voivodeship, Poland
Instytut Hematologii i Transfuzjologii /ID# 225478
Warsaw, Masovian Voivodeship, Poland
SP ZOZ Zespol Szpitali Miejskich w Chorzowie /ID# 225474
Chorzów, Silesian Voivodeship, Poland
IPO Lisboa FG, EPE /ID# 225072
Lisbon, , Portugal
Federal State Budgetary Scientific Institution N.N. Blokhin /ID# 225194
Moscow, Moscow, Russia
Regional Oncological Dispensary /ID# 225195
Penza, Penza Oblast, Russia
Samsung Medical Center /ID# 240882
Seoul, Seoul Teugbyeolsi, South Korea
Hospital Universitario Fundacion Jimenez Diaz /ID# 225476
Madrid, , Spain
Duplicate_Skane University Hospital Lund /ID# 224747
Lund, Skåne County, Sweden
National Taiwan University Hospital /ID# 224946
Taipei City, Taipei, Taiwan
China Medical University Hospital /ID# 224945
Taichung, , Taiwan
Ankara Univ Medical Faculty /ID# 225043
Ankara, , Turkey (Türkiye)
Istanbul University Istanbul Medical Faculty /ID# 225045
Istanbul, , Turkey (Türkiye)
Vehbi Koc vakfi Amerikan Hasta /ID# 225046
Istanbul, , Turkey (Türkiye)
Municipal Non-Profit Enterprise City Clinical Hospital 4 of Dnipro City Council /ID# 240575
Dnipro, , Ukraine
Derriford Hospital and the Royal Eye Infirmary /ID# 218731
Plymouth, Devon, United Kingdom
Leicester Royal Infirmary /ID# 240468
Leicester, England, United Kingdom
University College London Hospital /ID# 240467
London, Greater London, United Kingdom
University Hospital Southampton NHS Foundation Trust /ID# 225161
Southampton, Hampshire, United Kingdom
Blackpool Teaching Hospitals NHS Foundation Trust /ID# 225163
Blackpool, , United Kingdom
Clatterbridge Cancer Centre - Liverpool /ID# 218736
Liverpool, , United Kingdom
King's College Hospital NHS Foundation Trust /ID# 218735
London, , United Kingdom
The Royal Wolverhampton NHS Trust /ID# 225164
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-501522-38-00
Identifier Type: OTHER
Identifier Source: secondary_id
M19-388
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.